Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2012 1
2014 2
2015 2
2016 6
2017 2
2019 5
2020 5
2021 6
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL, Martin TG 3rd, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey AD Jr, Mullins RD, Eyquem J, Wells JA, Wiita AP. Ferguson ID, et al. Among authors: wolf jl. Nat Commun. 2022 Jul 15;13(1):4121. doi: 10.1038/s41467-022-31810-6. Nat Commun. 2022. PMID: 35840578 Free PMC article.
The development of potential antibody-based therapies for myeloma.
Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG 3rd, Liu B. Sherbenou DW, et al. Among authors: wolf jl. Blood Rev. 2015 Mar;29(2):81-91. doi: 10.1016/j.blre.2014.09.011. Epub 2014 Sep 28. Blood Rev. 2015. PMID: 25294123 Free PMC article. Review.
CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy.
Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, Chang H, Bridge M, Kwek SS, Cheung A, Bylsma SA, Hansen E, Wolf JL, Wong SW, Shah N, Roybal KT, Martin TG, Ye CJ, Fong L. Ledergor G, et al. Blood Adv. 2024 Apr 4:bloodadvances.2023012416. doi: 10.1182/bloodadvances.2023012416. Online ahead of print. Blood Adv. 2024. PMID: 38574299
CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.
Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. Ramkumar P, et al. Among authors: wolf jl. Blood Adv. 2020 Jul 14;4(13):2899-2911. doi: 10.1182/bloodadvances.2019001346. Blood Adv. 2020. PMID: 32589729 Free PMC article.
Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.
Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Sherbenou DW, et al. Among authors: wolf jl. J Clin Invest. 2016 Dec 1;126(12):4640-4653. doi: 10.1172/JCI85856. Epub 2016 Nov 14. J Clin Invest. 2016. PMID: 27841764 Free PMC article.
32 results